Vaxxas is targeting initial applications in infectious disease and oncology.

In December 2022, the Australian needle-free treatment specialist raised $23 million for its COVID-19 vaccine. Proceeds from the financing will be used to advance Vaxxas’ clinical programs and install its first manufacturing lines with capacity to support products through late-stage clinical studies and initial commercial production.